Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive Biotechnologies ClonoSeq MRD Assay for DLBCL Patients

Adaptive Biotechnologies has launched its ClonoSeq Assay to detect minimal residual disease (MRD) in blood for patients with diffuse large B-cell lymphoma (DLBCL). According to Adaptive, ClonoSeq can assess a patient's MRD status in DLBCL by measuring circulating tumor DNA (ctDNA). The assay is available in DLBCL as a CLIA-validated laboratory-developed test (LDT), and beginning this week, the company will accept DLBCL blood samples in Streck tubes to enable broader access to ctDNA-based MRD testing for clinicians and patients. Adaptive said ClonoSeq MRD testing is covered by Medicare in DLBCL, with coverage extending to all DLBCL patients regardless of line of therapy, treatment regimen, or testing timepoint.

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.